{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:32:58Z","timestamp":1765888378429},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Celltrion Healthcare Co., Ltd.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) into clinical practice has dramatically improve the clinical outcomes of individuals with rheumatoid arthritis (RA). However, bDMARDs are associated with high costs, which has resulted in restricted treatment access and a burden on medical insurance finances. Although biosimilars offer cost-saving, their effectiveness and safety must be established in Post-Marketing Surveillance (PMS). Infliximab (IFX), a chimeric monoclonal antibody to TNF-alpha, is the first bDMARD; its biosimilar, CT-P13, is the first biosimilar DMARD approved for RA treatment in Japan. We will evaluate whether switching from originator IFX to CT-P13 is not inferior for maintaining non-clinical relapse to continued treatment with originator IFX in RA patients achieving clinical remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/design:<\/jats:title>\n            <jats:p>This study is an interventional, multicenter, open-label, single-arm against historical control and noninferiority clinical trial with a 24-week follow-up. Eighty RA patients who are treated by originator IFX for \u226524 weeks and are achieving clinical remission will be included. Patients will be switched to CT-P13 with the unchanged dosing regimen. We will evaluate disease activity by measuring clinical disease activity indices and by using musculoskeletal ultrasound (MSUS). The primary endpoint is the ratio of patients who experience a nonclinical relapse during the study period. Important secondary endpoints are the changes from the baseline of the MSUS scores. We will also comprehensively analyze the serum levels of many biomarkers such as cytokines and chemokines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>The study results are expected to show the noninferiority of switching to CT-P13 over the continuation of originator IFX. The strength of this study is its prospective evaluation of therapeutic efficacy using not only clinical disease activity indices but also MSUS to accurately and objectively evaluate disease activity at the joint level among patients drawn from multiple centers with a standardized evaluation by MSUS. We will explore whether parameters at baseline can predict a nonclinical relapse after switching from originator IFX to CT-P13 by integrating multilateral assessments, i.e., clinical disease activity indices, MSUS findings, and serum biomarkers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>This study was registered in the Japan Registry of Clinical Trials (https:\/\/jrct.niph.go.jp) on October 11, 2019 as jRCTs071190030.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021151","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:07:16Z","timestamp":1595372836000},"page":"e21151","source":"Crossref","is-referenced-by-count":4,"title":["Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I)"],"prefix":"10.1097","volume":"99","author":[{"given":"Shin-ya","family":"Kawashiri","sequence":"first","affiliation":[{"name":"Departments ofCommunity Medicine"},{"name":"Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurika","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizu","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: Current evidence and future directions","volume":"75","author":"Schett","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/s10165-006-0532-0","article-title":"Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)","volume":"17","author":"Yamanaka","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R7-20230915","article-title":"Guidelines on evaluation of similar biotherapeutic products (SBPs)","year":"2009","journal-title":"XXX"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","article-title":"Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","article-title":"Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","article-title":"EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis","volume":"72","author":"Colebatch","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1136\/annrheumdis-2016-209646","article-title":"Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission","volume":"75","author":"D\u2019Agostino","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.23682","article-title":"Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis","volume":"58","author":"Naredo","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/14397595.2016.1221874","article-title":"Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs","volume":"27","author":"Kawashiri","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/rheumatology\/keu217","article-title":"Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis","volume":"53","author":"Nguyen","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/rheumatology\/ket405","article-title":"Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: Power Doppler subclinical synovitis is associated with bone erosion","volume":"53","author":"Kawashiri","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","article-title":"Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis","volume":"76","author":"Brocq","year":"2009","journal-title":"Joint Bone Spine"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/acr.23551","article-title":"Ultrasonographic efficacy of biologic and targeted synthetic disease-modifying antirheumatic drug therapy in rheumatoid arthritis from a multicenter rheumatoid arthritis ultrasound prospective cohort in Japan","volume":"70","author":"Nishino","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2007.078451","article-title":"Settings and artefacts relevant in colour\/power Doppler ultrasound in rheumatology","volume":"67","author":"Torp-Pedersen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"e000237","DOI":"10.1136\/rmdopen-2015-000237","article-title":"Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study","volume":"2","author":"D\u2019Agostino","year":"2016","journal-title":"RMD Open"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: A EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"},{"key":"R27-20230915","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.autrev.2012.11.009","article-title":"Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?","volume":"12","author":"Modena","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"Dorner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","article-title":"A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:02:00Z","timestamp":1694826120000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021151"}},"subtitle":["Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments"],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":33,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021151","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}